HC Wainwright Reiterates “Buy” Rating for Processa Pharmaceuticals (NASDAQ:PCSA)

Processa Pharmaceuticals (NASDAQ:PCSA)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $6.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 404.20% from the company’s current price.

Processa Pharmaceuticals Price Performance

Processa Pharmaceuticals stock opened at $1.19 on Thursday. The firm’s fifty day moving average price is $1.49 and its 200 day moving average price is $1.79. The company has a market capitalization of $3.40 million, a price-to-earnings ratio of -0.24 and a beta of 0.59. Processa Pharmaceuticals has a 12-month low of $1.19 and a 12-month high of $18.00.

Processa Pharmaceuticals (NASDAQ:PCSA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.03). Analysts forecast that Processa Pharmaceuticals will post -3.78 earnings per share for the current fiscal year.

Processa Pharmaceuticals Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.